SNCA and Fabry disease: To our knowledge, this is the first report showing that accumulation of SNCA directly contributes to lysosomal impairment and disease severity in FD in a substrate-independent fashion, which suggests that pharmacological targeting of SNCA could serve as an additional therapeutic strategy, especially for patients with Fabry nephropathy.